Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 1

Conditions

Sarcoma, Synovial 9Sarcoma 9Osteosarcoma 8Neoplasms 7Melanoma 7Liposarcoma, Myxoid 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Myelodysplastic Syndromes 6Leukemia, Myeloid, Acute 6Dendritic Cell Sarcoma, Interdigitating 6Sarcoma, Ewing 5Ovarian Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Burkitt Lymphoma 5Rhabdomyosarcoma 4Lymphoma, Follicular 4Leukemia, Prolymphocytic 4Triple Negative Breast Neoplasms 3Lymphoma, T-Cell 3Leukemia 3Esophageal Neoplasms 3Wilms Tumor 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2

Interventions

Temozolomide 48Bevacizumab 29Carmustine 17Erlotinib Hydrochloride 16Radiotherapy 14Irinotecan 14Surgical Procedures, Operative 10Sirolimus 10Imatinib Mesylate 10Carboplatin 10Sorafenib 9O(6)-benzylguanine 9Filgrastim 9Etoposide 8temsirolimus 7sargramostim 7Radiosurgery 7Radiation 7Procarbazine 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7aldesleukin 6Topotecan 6Thalidomide 6Vorinostat 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Hydroxyurea 5Gefitinib 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × fludarabine × Sarcoma × Clear all
NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 25 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡